Our research aims to provide a better understanding of bone loss and abnormalities in metabolic bone diseases and bone metabolism in physiological and pathological settings in the field of osteoimmunology. Osteoclasts are of great therapeutic importance for nearly all forms of metabolic bone disease. As such, our lab focuses on investigating new molecular, epigenetic, genetic, and metabolic mechanisms governing the activity of osteoclasts that can be targeted as potential therapeutic strategies for hyperactive osteoclasts in pathological conditions, such as osteoporosis, rheumatoid arthritis, and inflammatory osteolysis. Our lab applies cutting edge cellular and molecular techniques, including genome-wide sequencing, and uses human disease samples and various mouse models to accomplish basic and translational research.
Please see the detailed projects on our lab website: Parkmin Laboratory
Associate Professor, Department of Medicine, Weill Medical College of Cornell University
Associate Scientist, Arthritis and Tissue Degeneration Program, Hospital for Special Surgery
For more publications, please see the PubMed listing.
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Research staff at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however, HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists Research staff collaborations with outside companies if the Research staff member received any payment during the prior year or expects to receive any payment in the next year. The disclosures are based on information provided by the Research staff and other sources and are updated regularly. Current ownership interests and leadership positions are also listed. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Park-Min as of March 28, 2023.
Amgen, Inc. - Speakers' Bureau
By disclosing the collaborations of HSS Research staff with industry on this website, HSS and its Research staff make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit payment of royalties on products developed by him/her that are used on patients at HSS.
Feel free to ask the Research staff member about their relationship(s).